AXIS Clinicals Announces Dr. Yati Chugh as CEO
Published: Jan 31, 2013
Dr. Chugh brings over two decades of experience in conducting pre-clinical, Bioequivalence / Bioavailability (BA/BE) studies and clinical research. He has extensive experience in areas of CNS, CVS, drug metabolism / pharmacokinetics and clinical pharmacology.
“As AXIS Clinicals is one of the leading CRO’s of the country,that provides clinical studies on both male and female healthy patient population in virtually all therapeutic areas, I am looking forward to our continued leadership in delivering the AXIS Advantage of timely deliveries, accuracy and quality in accordance to global standards to our clients & partners,” Dr. Yati Chugh, CEO said. “Our fundamental focus is to provide our customers a complete clinical research portfolio under one roof that will help them achieve the competitive advantage needed in staying ahead,” he added.
Dr. Chugh holds a doctorate degree from PGIMER, Chandigarh and has published about 45 scientific papers in reputed national and international peer-reviewed journals. He has completed his Master’s and Ph.D in pharmacology from PGIMER, Chandigarh and graduated in B.Pharm from Department of Pharmaceutical Sciences, Punjab University, Chandigarh. He has about 25 patents to his credit and is a member of all the major international bodies of pharmacology and is a reviewer in major Journals of Pharmacology.
Prior to joining AXIS Clinicals, Dr. Chugh was heading Lotus Labs as Managing Director. He has been associated with several reputed biopharmaceutical companies like Wockhardt, Intas Pharmaceuticals, Torrent Pharmaceuticals Limited for over two decades.
About AXIS Clinicals
AXIS Clinicals Limited, one of India’s leading CRO is committed to serving the biopharmaceutical industry by leveraging two powerful trends impacting the world of Clinical Research – globalisation and full spectrum offering. Established in September 2004, the company has completed over 1500 clinical studies, 300 ANDA studies and received 50 product approvals from regulatory agencies. The company facilities have been accredited by DCGI (Drugs Controller General, India), NABL (National Accreditation Board for Testing and Calibration Laboratories – ISO 15189:2003) and inspected by US-FDA, UK-MHRA, Brazil-ANVISA and France AFSSAPS and conforms to ICH and CDSCO-GCP & GLP Guidelines. For further details, please visit – www.axisclinicals.com
For further details, contact:
Shankar Chelluri, S Paradigm Consultants, P: +91.99490.93501